The Centers for Disease Control and Prevention (CDC) is being asked to provide data on how many children infected with respiratory syncytial virus (RSV) have received a COVID-19 vaccine prior to their diagnosis, according to Aaron Siri, a lawyer representing the Informed Consent Action Network (ICAN).
“Our firm, on behalf of our client Informed Consent Action Network, sent the letter to the CDC asking for follow-up on this issue,” Siri wrote in an email to The Epoch Times, adding that FOIA requests have also been submitted.
“If the CDC chooses not to respond to the letter, they will at least be required pursuant to law to respond to the FOIA requests,” Siri said.
RSV is a respiratory virus that usually causes cold-like symptoms in people of all ages. Doctors say that the virus is so common that many children will have been infected with it before they are two years old.
In most people, RSV is mild and will go away in a week or two, but for some—who are immunocompromised or have a lung or heart disease—the viral infection can be quite severe.
Changes in societal behavioral and non-pharmaceutical interventions (NPIs), including lockdowns and mask-wearing, during COVID-19 changed the spread of SARS-CoV-2 and the “predictable seasonal circulation patterns of many endemic viral illnesses in children,” the authors wrote.
SARS-CoV-2 is the virus that causes COVID-19.
Other Possible ExplanationsThere is ongoing debate on the possible explanations for the unusual RSV wave in the spring to summer of 2021 and 2022, and the current early fall surge.
A third possible reason for the RSV wave is that COVID-19 injections may increase the risk of infection from other diseases and why several experts, including ICAN, suggest that the vaccine status of children diagnosed with RSV be tracked.
COVID-19 mRNA Injections and RSV
Besides the NPIs and societal behavioral changes that occurred during the pandemic, COVID-19 injections were administered to pregnant women and children ages 6 months to 17 years.
Events of RSV were reported by 0.8 percent of the participants who received the Moderna jab compared to 0.5 percent in the placebo for children 6 to 23 months old.
In children aged 2 to 5 years, 0.4 percent of vaccinated children reported RSV infection, whereas less than 0.1 percent in the placebo did.
In children aged 6 to 11, 0.3 percent of those vaccinated experienced RSV versus zero in the placebo group.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC), the panel that advises the Food and Drug Administration (FDA) on vaccines, in June 2022 “stressed the importance of continued post-authorization safety surveillance, in particular for myocarditis/pericarditis and for certain respiratory infections (RSV and pneumonia) in the youngest age group, for which imbalances of uncertain clinical significance were observed in the clinical trial, and febrile seizures given the rates of fever observed in the youngest age group.”
Despite the higher rates of RSV in the vaccinated group, the panel went ahead and voted to recommend the vaccine, claiming that “overall, the frequency and clinical course for these events do not appear unusual given the age group of the study population and the season (fall-winter) during which the study took place, and the observed imbalance could be due to chance.”
Symptoms and Treatment for RSVSome of the symptoms of RSV include coughing, runny nose, fever, sneezing, and wheezing.
The CDC says that children at high risk of severe disease can receive a monoclonal antibody injection, palivizumab, prior to RSV season as prophylaxis. People with RSV are recommended to take acetaminophen or ibuprofen to reduce fever and relieve pain, and to keep hydrated. Parents should discuss with their doctor before giving their child an over-the-counter cold medicine.
The CDC, the FDA, Pfizer, and Moderna did not respond to The Epoch Times' request for comment.